JP2018506995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506995A5 JP2018506995A5 JP2017562971A JP2017562971A JP2018506995A5 JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5 JP 2017562971 A JP2017562971 A JP 2017562971A JP 2017562971 A JP2017562971 A JP 2017562971A JP 2018506995 A5 JP2018506995 A5 JP 2018506995A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- transgene
- cell
- sequence encoding
- dhfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120329P | 2015-02-24 | 2015-02-24 | |
| US62/120,329 | 2015-02-24 | ||
| US201562120790P | 2015-02-25 | 2015-02-25 | |
| US62/120,790 | 2015-02-25 | ||
| US201562175794P | 2015-06-15 | 2015-06-15 | |
| US62/175,794 | 2015-06-15 | ||
| PCT/US2016/019288 WO2016138091A2 (en) | 2015-02-24 | 2016-02-24 | Selection methods for genetically-modified t cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506995A JP2018506995A (ja) | 2018-03-15 |
| JP2018506995A5 true JP2018506995A5 (https=) | 2019-03-14 |
| JP6947647B2 JP6947647B2 (ja) | 2021-10-13 |
Family
ID=56464271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562971A Active JP6947647B2 (ja) | 2015-02-24 | 2016-02-24 | 遺伝子改変ｔ細胞の選択方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10808230B2 (https=) |
| EP (2) | EP3804741A3 (https=) |
| JP (1) | JP6947647B2 (https=) |
| KR (1) | KR20170117095A (https=) |
| CN (1) | CN107667169B (https=) |
| AU (2) | AU2016222850B2 (https=) |
| CA (1) | CA2976126A1 (https=) |
| WO (1) | WO2016138091A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3656864A1 (en) | 2014-02-14 | 2020-05-27 | Board of Regents, The University of Texas System | Chimeric antigen receptors and methods of making |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| KR102615825B1 (ko) | 2015-03-11 | 2023-12-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전위효소 폴리펩타이드 및 이의 용도 |
| US10633445B2 (en) | 2015-09-15 | 2020-04-28 | Board Of Regents The University Of Texas System | T-cell receptor (TCR)-binding antibodies and uses thereof |
| US11059879B2 (en) | 2015-10-27 | 2021-07-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US10780119B2 (en) | 2017-05-24 | 2020-09-22 | Effector Therapeutics Inc. | Methods and compositions for cellular immunotherapy |
| CN109136282A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞的构建方法 |
| WO2020102726A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Method for manufacturing of human hybrid regulatory t/th2 cells (hybrid treg/th2 cells) from de-differentiated t cells |
| CN113573778B (zh) | 2018-11-16 | 2025-05-13 | 拉帕治疗有限公司 | 使用诱导性调节性T（iTREG）细胞进行的ALS治疗 |
| KR102594009B1 (ko) | 2021-02-01 | 2023-10-24 | 서울대학교산학협력단 | 형질전환 생식세포의 제조 방법 및 이를 이용한 형질전환 동물의 제조 방법 |
| EP4408169A4 (en) * | 2021-09-30 | 2025-10-29 | Univ Southern California | Human hepatocyte culture medium and conditioned medium of in vitro cultured human hepatocyte cells and their uses |
| CN114740196B (zh) * | 2022-04-08 | 2023-04-18 | 中南大学湘雅二医院 | 标志物及其在制备评价机体免疫功能的产品中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102575227A (zh) * | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| EP2496244B8 (en) * | 2009-11-02 | 2017-11-22 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| JP2016539929A (ja) | 2013-10-25 | 2016-12-22 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 免疫療法のためのポリクローナルγδＴ細胞 |
| KR102348577B1 (ko) * | 2013-11-22 | 2022-01-06 | 셀렉티스 | 면역요법을 위한 화학요법 약물 저항성 ｔ―세포들의 조작 방법 |
| EP3656864A1 (en) | 2014-02-14 | 2020-05-27 | Board of Regents, The University of Texas System | Chimeric antigen receptors and methods of making |
| CA2945320A1 (en) * | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| EP3134515B1 (en) | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| AU2015343013B2 (en) | 2014-11-05 | 2020-07-16 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| KR102615825B1 (ko) | 2015-03-11 | 2023-12-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전위효소 폴리펩타이드 및 이의 용도 |
| US10633445B2 (en) | 2015-09-15 | 2020-04-28 | Board Of Regents The University Of Texas System | T-cell receptor (TCR)-binding antibodies and uses thereof |
| US11059879B2 (en) | 2015-10-27 | 2021-07-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
-
2016
- 2016-02-24 EP EP20191615.2A patent/EP3804741A3/en not_active Withdrawn
- 2016-02-24 CA CA2976126A patent/CA2976126A1/en active Pending
- 2016-02-24 US US15/552,821 patent/US10808230B2/en active Active
- 2016-02-24 AU AU2016222850A patent/AU2016222850B2/en not_active Ceased
- 2016-02-24 WO PCT/US2016/019288 patent/WO2016138091A2/en not_active Ceased
- 2016-02-24 EP EP16741163.6A patent/EP3261656B1/en active Active
- 2016-02-24 CN CN201680011714.XA patent/CN107667169B/zh not_active Expired - Fee Related
- 2016-02-24 JP JP2017562971A patent/JP6947647B2/ja active Active
- 2016-02-24 KR KR1020177024195A patent/KR20170117095A/ko not_active Withdrawn
-
2020
- 2020-09-04 US US17/013,195 patent/US20210054346A1/en not_active Abandoned
-
2021
- 2021-06-02 AU AU2021203606A patent/AU2021203606A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506995A5 (https=) | ||
| Krueger et al. | Two sequential activation modules control the differentiation of protective T helper-1 (Th1) cells | |
| US10858660B2 (en) | Gold optimized CAR T-cells | |
| Fazilleau et al. | The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding | |
| Schrama et al. | Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue | |
| Gattinoni et al. | T memory stem cells in health and disease | |
| Strutt et al. | Memory CD4+ T-cell–mediated protection depends on secondary effectors that are distinct from and superior to primary effectors | |
| Stritesky et al. | The transcription factor STAT3 is required for T helper 2 cell development | |
| TW202134285A (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 | |
| JP2021073440A (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| CN115697387A (zh) | 抗bcma嵌合抗原受体的用途 | |
| US20210393694A1 (en) | Coordinating Gene Expression Using RNA Destabilizing Elements | |
| BR112020007710A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| ES2910227T3 (es) | Composición y métodos para la estimulación y expansión de células T | |
| IL310711B1 (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| JP2017513520A5 (https=) | ||
| AU2016222850A1 (en) | Selection methods for genetically-modified T cells | |
| CN113785048B (zh) | 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法 | |
| Suematsu et al. | PiggyBac transposon-mediated CD19 chimeric antigen receptor-T cells derived from CD45RA-positive peripheral blood mononuclear cells possess potent and sustained antileukemic function | |
| Beltra et al. | Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state | |
| Trella et al. | CD40 ligand‐expressing recombinant vaccinia virus promotes the generation of CD8+ central memory T cells | |
| Metcalfe et al. | Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties | |
| US9234175B2 (en) | Creating bioengineered lymph nodes | |
| Fousteri et al. | Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure | |
| van der Heide et al. | Prolonged but finite antigen presentation promotes reversible defects of “helpless” memory CD8+ T cells |